Ex­clu­sive: Aven­zo picks up an­oth­er ADC, this time with mul­ti-part­nered Du­al­i­ty­Bio

Aven­zo Ther­a­peu­tics, a well-fund­ed biotech that has in-li­censed treat­ment can­di­dates from Chi­nese drug de­vel­op­ers, has forged its third deal since re­assem­bling much of the Turn­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER